Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1933 1
1934 2
1939 1
1944 1
1947 1
1948 2
1949 5
1950 4
1951 9
1952 2
1953 6
1954 4
1955 5
1956 5
1957 4
1958 3
1959 3
1960 13
1961 6
1962 3
1963 9
1964 10
1965 11
1966 11
1967 14
1968 11
1969 11
1970 6
1971 12
1972 15
1973 16
1974 17
1975 25
1976 28
1977 24
1978 24
1979 19
1980 27
1981 25
1982 38
1983 40
1984 42
1985 43
1986 63
1987 41
1988 33
1989 56
1990 65
1991 61
1992 70
1993 59
1994 54
1995 61
1996 68
1997 73
1998 71
1999 72
2000 64
2001 60
2002 67
2003 74
2004 68
2005 77
2006 86
2007 94
2008 104
2009 110
2010 95
2011 109
2012 110
2013 122
2014 127
2015 129
2016 99
2017 119
2018 123
2019 150
2020 143
2021 203
2022 169
2023 156
2024 171
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,923 results

Results by year

Filters applied: . Clear all
Page 1
Microenvironmental stiffness induces metabolic reprogramming in glioblastoma.
Sohrabi A, Lefebvre AEYT, Harrison MJ, Condro MC, Sanazzaro TM, Safarians G, Solomon I, Bastola S, Kordbacheh S, Toh N, Kornblum HI, Digman MA, Seidlits SK. Sohrabi A, et al. Among authors: harrison mj. Cell Rep. 2023 Oct 31;42(10):113175. doi: 10.1016/j.celrep.2023.113175. Epub 2023 Sep 26. Cell Rep. 2023. PMID: 37756163 Free PMC article.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Among authors: harrison mr. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
Prior Authorization.
Harrison MB. Harrison MB. Neurology. 2023 Nov 14;101(20):905-906. doi: 10.1212/WNL.0000000000207790. Epub 2023 Aug 30. Neurology. 2023. PMID: 37648531 Free PMC article. No abstract available.
Presidential Forum.
Ellison EC, Ponsky JL, Harrison MR, McGrath MH, Angelos P, Krummel TM. Ellison EC, et al. Among authors: harrison mr. Ann Surg. 2019 Oct;270(4):573-584. doi: 10.1097/SLA.0000000000003421. Ann Surg. 2019. PMID: 31274654 No abstract available.
Sex in the Time of COVID-19.
Harrison M. Harrison M. J Rheumatol. 2023 Oct;50(10):1208-1210. doi: 10.3899/jrheum.2023-0444. Epub 2023 Jul 15. J Rheumatol. 2023. PMID: 37453740 No abstract available.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: harrison mr. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Tykodi SS, et al. Among authors: harrison mr. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844. J Immunother Cancer. 2022. PMID: 35210307 Free PMC article. Clinical Trial.
Type 2 Biomarkers and Bronchiectasis.
Rutherford RM, Harrison MJ. Rutherford RM, et al. Among authors: harrison mj. Lung. 2024 Aug;202(4):365-366. doi: 10.1007/s00408-024-00716-z. Lung. 2024. PMID: 38884648 No abstract available.
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M, Pirrie S, Bowden SJ, Dunachie SJ, Richter A, Lim Z, Satsangi J, Cook G, Pope A, Hughes A, Harrison M, Lim SH, Miller P, Klenerman P; PITCH consortium; Basu N, Gilmour A, Irwin S, Meacham G, Marjot T, Dimitriadis S, Kelleher P, Prendecki M, Clarke C, Mortimer P, McIntyre S, Selby R, Meardon N, Nguyen D, Tipton T, Longet S, Laidlaw S, Orchard K, Ireland G; CONSENSUS; Thomas D, Kearns P, Kirkham A, McInnes IB; OCTAVE Collaborative Group. Barnes E, et al. Among authors: harrison m. Nat Med. 2023 Jul;29(7):1760-1774. doi: 10.1038/s41591-023-02414-4. Epub 2023 Jul 6. Nat Med. 2023. PMID: 37414897 Free PMC article.
3,923 results